news-med.jpg

Evotec partner Haplogen enters into collaboration with Bayer

Focus on pulmonary diseases with high unmet medical need Integrated Haplogen-Bayer collaboration builds upon pulmonary portfolio created by Evotec and Haplogen Evotec will participate in undisclosed upfront as well as potential milestone and royalty-based payments from Bayer to Haplogen

Topics: Corporate, Evotec, Haplogen, Bayer, pulmonary diseases Read More

Evotec receives milestone payment for start of Phase II trial in its multi-target alliance with Bayer

Hamburg, Germany, 19 July 2018: Hamburg, Germany, 19 July 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its multi-target alliance with Bayer in the field of endometriosis has advanced a promising small molecule into Phase II clinical development ...

Topics: Corporate, Evotec, Bayer, Endometriosis, Chronic cough Read More

Evotec and Bayer Advance Third Endometriosis Programme into Phase I Clinical Development

Hamburg, Germany, 18 April 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its multi-target alliance with Bayer has advanced another promising small molecule into Phase I for the treatment of endometriosis, a painful, debilitating reproductive ...

Topics: Corporate, Bayer, Endometriosis, Phase I Read More

Most Read

Posts by Topic